Chao Pharmaceutical Manufacturer Closing Doors
04/27/2010
The center, which opened in 2005 through a $5 million gift from Purdue alumni, is a pharmaceutical manufacturing facility that produces and distributes legacy and small-volume drugs.
As part of a humanitarian effort, the Chao Center will continue manufacturing and distributing the multidrug-resistant tuberculosis drug Seromycin and other life-saving legacy drugs until new manufacturers are found. In 2007, through an agreement with Eli Lilly and Co., the Chao Center became the sole producer of Seromycin for patients in North America.
Outplacement services for the 12 center employees will be provided. Transfers for employment opportunities at the Purdue Research Foundation also will be offered if comparable positions are available.
A new manufacturer of small-volume drug batches will be sought to move into the facility.
The main consideration behind the closing is that the Chao Center has not been able to become self-sustaining during its five-year operation. Contributing factors include the economic downturn and the challenges with producing small-volume drugs, according to Joseph B. Hornett, senior vice president, treasurer and COO of the Purdue Research Foundation.
Project Announcements
Fukoku Korea Plans Henry County, Virginia, Manufacturing Operations
03/13/2026
Germany-Based Sennheiser Group Plans Nashville, Tennessee, Operations
03/12/2026
Interstate Group Expands Giles County, Virginia, Production Operations
03/11/2026
Shinhwa Auto USA Expands Auburn, Alabama, Operations
03/11/2026
General Atomics Expands Shannon, Mississippi, Production Operations
03/11/2026
Starbucks Plans Davidson County, Tennessee, Corporate Operations
03/08/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Preparing for the Next USMCA Shake-Up
Q4 2025
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
The New Industrial Revolution in Biotech
Q4 2025
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
The Skilled Trades Are Ready for a Digital Future
Q4 2025